AKT1 and breast cancer: A recent study showed that mutation perturbing the lipid and protein phosphatase activities of PTEN caused activation of Akt/mTOR/p70S6K signaling and chemoresistance, whereas rapamycin synergized with doxorubicin to inhibit growth of breast cancer cells (Steelman et al. 2008).